SAN DIEGO, April 21, 2026 /PRNewswire/ — Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced updated interim data from its Phase 1/2 study evaluating…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
